Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製葯(控股)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017 FINANCIAL HIGHLIGHTS

Unaudited

For the six months ended 30 June

2017

2016

Change

Revenue (RMB'000)

491,056

418,449

17.4%

Gross Profit (RMB'000)

340,832

255,703

33.3%

Gross Profit Margin

69.4%

61.1%

+8.3 percentage points

Profit before tax (RMB'000)

186,309

165,077

12.9%

Profit for the period attributable to

owners of the parent (RMB'000)

148,968

131,480

13.3%

Net Profit Margin

30.3%

31.4%

-1.1 percentage points

Earnings per share - basic (RMB)

0.1859

0.1638

13.5%

Interim dividend per share (HK$)

0.03

0.03

0.0%

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

The board (the "Board") of directors (the "Directors") of Dawnrays Pharmaceutical (Holdings) Limited (the "Company") is pleased to announce the unaudited consolidated interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 June 2017 (the "period"). These interim results have been reviewed by the audit committee of the Company.

INTERIM DIVIDEND

The Board has resolved to declare an interim dividend of HK$0.03 per share for the year ending 31 December 2017, approximately amounting to a total sum of HK$23,805,000 (approximately equivalent to RMB20,373,000).

For the six months ended 30 June

2017

2016

(Unaudited)

(Unaudited)

Notes

RMB'000

RMB'000

Revenue

3

491,056

418,449

Cost of sales

(150,224)

(162,746)

Gross profit

340,832

255,703

Other income and gains

3

13,713

11,497

Selling and distribution expenses

(102,392)

(47,342)

Administrative expenses

(40,012)

(28,911)

Other expenses

(24,159)

(25,793)

Finance costs

4

(13)

(77)

Share of profits and losses of:

Associates

(1,660)

-

PROFIT BEFORE TAX

5

186,309

165,077

Income tax expense

6

(37,341)

(33,597)

PROFIT FOR THE PERIOD

148,968

131,480

Attributable to:

Owners of the parent

148,968

131,480

EARNINGS PER SHARE ATTRIBUTABLE TO

ORDINARY EQUITY HOLDERS OF THE PARENT

8

- basic, for profit for the period

RMB0.1859

RMB0.1638

- diluted, for profit for the period

RMB0.1859

RMB0.1636

For the six months ended 30 June

2017

2016

(Unaudited)

(Unaudited)

RMB'000

RMB'000

PROFIT FOR THE PERIOD

148,968

131,480

Other comprehensive (loss)/income to be reclassified to profit or loss in

subsequent periods:

Exchange differences

(2,410)

649

OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD,

NET OF TAX

(2,410)

649

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD,

NET OF TAX

146,558

132,129

Attributable to:

Owners of the parent

146,558

132,129

NON-CURRENT ASSETS

Notes

30 June

2017

(Unaudited) RMB'000

31 December

2016

(Audited)

RMB'000

Property, plant and equipment

544,976

566,321

Land use rights

39,650

40,175

Construction in progress

7,869

5,776

Intangible assets

25,205

24,909

Investments in associates

48,670

-

Deferred tax assets

6,625

6,729

Total non-current assets

672,995

643,910

CURRENT ASSETS

Inventories

9

118,944

124,746

Trade and notes receivables

10

265,239

225,660

Prepayments, deposits and other receivables

380,626

220,958

Equity investments at fair value

through profit or loss

8,154

7,794

Cash and bank

534,453

663,296

Total current assets

1,307,416

1,242,454

CURRENT LIABILITIES

Trade and notes payables

11

93,227

87,938

Other payables and accruals

110,996

98,104

Interest-bearing bank loans

-

9,104

Income tax payable

20,033

5,510

Total current liabilities

224,256

200,656

Net current assets

1,083,160

1,041,798

Total assets less current liabilities

1,756,155

1,685,708

NON-CURRENT LIABILITIES

Government grants

2,248

2,248

Deferred tax liabilities

47,663

46,704

Total non-current liabilities

49,911

48,952

Net assets

1,706,244

1,636,756

Dawnrays Pharmaceutical (Holdings) Ltd. published this content on 22 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 August 2017 04:42:09 UTC.

Original documenthttp://en.dawnrays.com/UploadFiles/AnnmentFile/e_DAWNRAYS(e)_announcement 170822.pdf

Public permalinkhttp://www.publicnow.com/view/98476311CEA3CB1B6F77CB3CB74ED77F562B28D2